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A PHASE II RANDOMIZED OPEN-LABEL STUDY ANTI-CMV HYPERIMMUNE
GLOBULIN VS STANDARD IGIV FOR PREVENTION OF CYTOMEGALOVIRUS
(CMV) REACTIVATION IN HYPOGAMMAGLOBULINEMIC ADULT ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (AHSCT)
Bubalo, J.S., Leis, J.F., Curtin, P.T., Simic, A., Subbiah, N.,
Fowler, C., Dunn, A., Grant, B., Maziarz, R.T. Oregon Health and
Science University Hospital, Portland, OR.
Immune globulin is frequently given in the post-transplant phase of
allogeneic HSCT as part of pre-emptive anti-CMV therapy. The goal
of therapy is to reduce the incidence of CMV reactivation and the
subsequent sequelae of CMV disease, to minimize GVHD, and to
limit bacterial infections. Previous IGG replacement strategies pro-
vided scheduled IGIV replacement empirically, without regard for
physiologic hypogammaglobulinemia. The primary aim of this study
was to examine whether anti-CMV hyperimmune globulin (Cyto-
gam®) versus standard IGIV reduced the incidence of CMV activa-
tion in hypogammaglobulinemic patients. Ablative or nonmyeloabla-
tive, CMV, AHSCT patients were monitored biweekly for IGG
levels and received 200 mg/kg QOWof their designated agent if their
IGG was 400 mg/dl during the ﬁrst 120 days after HSCT. Weekly
CMV screening was performed. Antiviral therapy was begun for
evidence of molecular reactivation. A quantitative PCR based assay
was used in the majority of patients and 2 consecutive values 400
copies or 1 value 	400 copies resulted in initiation of antiviral ther-
apy. Ninety patients were enrolled at OHSU between 09/00 and
07/04. Forty-six were randomized to IGIV and 44 to Cytogam®.
Three patients randomized to Cytogam® received 1 dose of IGIV and
4 patients received additional IGIV for therapeutic reasons: ITP(1),
CMV infection (2), parvovirus (1). Groups were demographically
similar for age, gender, and transplant type (URD vs sib). Sixty-two of
90 (69%) patients completed 120 days, 29 (32%) have completed 2
years of follow-up, and 8 are still being actively followed. Forty-two of
90 patients never had an IGG  400 and received no study drug.
Twenty Cytogam® and 28 IVIG patients received study drug by 2
years. Eighteen of 21 patients receiving IVIG and 9/16 patients
receiving Cytogam® had CMV activation in the ﬁrst 120 days (P 
.05) (Table1). There were 2 cases of CMV disease: IGIV-colitis
[survived], Cytogam®-pneumonia [perished]). There were no deaths
attributed to either drug and a single related adverse event was re-
corded, rigors related to the too rapid infusion of Cytogam®. Of the
28 early deaths on this study, 10 were from infections, 3 graft failure,
5 pulmonary, 4 recurrence, 3 GVHD, 1 MOF, and 1 other. In this
small study of hypogammaglobulinemic AHSCT patients, IGG re-
placement with Cytogam® was associated with decreased rates of
CMV activation in the ﬁrst 120 days.







No drug/no CMV 10 10
No drug/CMV Activation 11 11
Drug/no CMV 11 8
Drug/CMV activation 9 20
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A SINGLE LOW DOSE OF RASBURICASE FOR TREATMENT OF HYPER-
URICEMIA IN PATIENTS WITH MALIGNANT DISEASES
Triﬁlio, S.M., Gordon, L.I., Tallman,M.S., Evens, A., Singhal, S., Rashid, K.,
Fishman, M., Masino, K., Mehta, J. Northwestern University, Chicago, IL.
Hyperuricemia is a major feature of tumor lysis syndrome (TLS)
in patients with hematololoic malignancies. Because of high tumor
burden or pre-existing renal dysfunction, a conventional approach
with hydration, alkalinization, and allopurinol may not be sufﬁ-
cient to lower uric acid levels rapidly. Rasburicase, a recombinant
urate oxidase enzyme, converts uric acid to soluble allantoin re-
ducing the risk of renal events. The approved dose is 0.15-0.2
mg/kg/d for 3-7 days. The cost is $255/mg corresponding to
approximately $15,000/5day for an average adult. Having had
success with variable lower doses and frequency in a small number
of patients (Triﬁlio et al, ASH 2004), we treated patients with ﬁxed
single doses of the drug with close monitoring of biochemical
parameters. Patients received hydration and allopurinoal as well.
Records of 51 patients treated with single-dose rasburicase were
reviewed with IRB approval. The rasburicase dose used was 3 mg
(n  44), 4.5 mg (n  3), or 6 mg (n  4). The mean baseline uric
acid for the 3 mg group was 10.2 and serum creatinine was 2.9, and
for the combined 4.5/6 mg group, 13 and 2.7. After a single 3 mg
dose, mean uric acid and creatine fell to 5.7 (44% decline) and 2.7
(7% decline) at 24 hours and 4.0 (61% decline) and 2.5 (14%
decline) at 48 hours, respectively. Uric acid levels were in the
normal range (8) in 91% of patients at 24 hours and in all at 48
hours. After a single 4.5/6 mg dose, uric acid and creatinine fell to
8.8 (32% decline) and 2.3 (15% decline) at 24 hours and 4.8 (63%
decline) and 2.2 (19% decline) at 48 hours, respectively. Uric acid
levels were within the normal range at 48 hours in all 7 patients.
Importantly, uric acid levels at 24 hours were within the normal
range in 46 of 47 patients with baseline uric acid 15. All 51
patients, including those with baseline uric acid 	15, achieved
nomral levels within 48 hours. A week after rasburicase, all 51
patients had maintained uric acid levels 8, and had experienced
improvement in creatine to 2.0. No additional renal dysfunction
developed in any patient, and no patient required hemodialysis
(myeloma patients with end-stage renal disease undergoing HSCT
continued hemodialysis). We conclude that a single low dose of
rasburicase is effective in lowering elevated serum uric acid levels
to normal with preservation of renal function. Signiﬁcant cost
savings with this approach (94-97% cost reduction) should reduce
the reluctance to use rasburicase in patients with elevated uric acid
levels.
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RISK FACTORS ASSOCIATED WITH MORTALITY AMONG PERSONS WITH
BREAKTHROUGH ZYGOMYCOSIS AND PRIOR VORICONAZOLE EXPO-
SURE
Triﬁlio, S.M., Bennett, C.L., Yarnold, P.R., Mehta, J., Palella, F.,
Kennedy, L., Parada, J., Blum, W., Kontoyiannis, D. 1. Northwestern
Memorial Hospital, Chicago, IL; 2. Wake Forest University Hospital,
Salem-Winston, NC; 3. Loyola Medical Center, Maywood, IL; 4. Ohio
State University, Columbus, OH; 5. M. D. Anderson Cancer Center,
Houston, TX.
Rates of Zygomycosis have been increasing, predominantly in
patients with hematologic malignancy with or without stem cell
transplant. Proposed factors associated with this change are in-
creasing use of voriconazole for treatment of Aspergillosis. With
the marked increase in the number of cases comes uncertainty of
risk factors for mortality. Investigators from RADAR identiﬁed
factors associated with higher risk of death with voriconazole
associated Zygomycosis. Cases from 13 cancer centers were col-
lected on a standardized case report form, including diagnosis,
species, established risk factors, steroid use, reason for use, con-
comitant infection, surgery, therapy, and outcome. Criteria in-
cluded a minimum of 5 days exposure, clinical diagnosis, and
conﬁrmation with tissue or cytology. Results: 58 patients were
identiﬁed with Zygomycosis and prior voriconazole exposure. Two
thirds had transplants. Overall mortality was 75%. Fifty patients
received voriconazole as prophylaxis. Due to very high mortality
along all categories tested, multivariate analysis identiﬁed only
steroid use and Rhizopus species as signiﬁcant risk factors. A
number of striking observations can be reported. Mortality by
transplant type: related 53% versus unrelated 80%; mortality by
site of infection; lungs  87% versus sinus  58%; mortality by
days of exposure 21days  24% versus 	21 days  77%; mor-
170
tality by surgery 50% versus no surgery 76%. The number of
patients who had HSCT increased over time: 30days  7,
30days–100days  9, and 	100days  15. Caspofungin used in
23%. Concommitant infection seen in 60% of patients. Mortality
for patients treated with amphotericin was 	75%. Discussion:
The characteristics of patients and outcomes for voriconazole ex-
posure are typical for Zygomycosis infection from any cause in
addition to steroid and Rhizopus species. Reports are from diverse
geographical sites around the USA.Voriconazole is being used off
label as prophylaxis without data to support efﬁcacy. One institu-
tion reported voriconazole an independent risk factor for Zygo-
mycosis. Breakthrough infections are common with other azoles,
so our ﬁndings here are not unexpected. Trials are needed deter-
mine if cases of Zygomycosis with voriconazole are offset by a
more pronounced decrease in Aspergillosis and other voriconazole
susceptible organism. We urge caution with indiscriminate pro-
phylaxis and empiric treatment. Diagnosis of infection with prior
voriconazole exposure requires appropriate treatment with Zygo-
mycosis coverage.
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NAUSEA AND VOMITING (N AND V) IN BONE MARROW TRANSPLANT
(BMT) PATIENTS—AN INVESTIGATION OF THE INCIDENCE, TIMING,
AND RELATED FACTORS
Lees, J., Marotti, R. Royal Adelaide Hospital, Pharmacy Department,
Adelaide, South Australia, Australia.
Background: Patients receiving high dose chemotherapy
(HDCT) pre-BMT are at risk of N and V from multiple causes—
highly emetic conditioning chemotherapy  Total Body Irradia-
tion; prior chemotherapy experiences; concomittant medications
such as anti-infectives, opioid analgesics, immunosuppressants
which may add to N and V; regimen related toxicity such as
mucositis may play a role; nasoenteric feeding (N/E) is sometimes
used. Whereas evidence based antiemetic guidelines are available
for standard chemotherapy, they have not yet been accepted for
BMT. Information on our own BMT patients had not been col-
lected. Aim: To investigate the incidence, timing, and factors
affecting N and V in BMT patients. Methods: Patients were
interviewed to obtain consent, history of previous emesis and their
risk factors for emesis. HDCT started on day 7 to 2 depending
on protocol, and transplant on day 0. Patients were given a diary
and education on how to record N and V daily until discharge.
Standard antiemetics were given during HDCT. Chemotherapy,
nursing emesis scores, all medications, incidence of mucositis, and
use of N/E feeding was recorded. Results: There were 21 patients,
52% male, mean age 51. Conditioning regimens included high
dose melphalan, cyclophosphamide/TBI, Bu/Cy/Etoposide, and
BEAM. Most patients had experienced prior CT-induced nausea
(81%) and vomiting (62%). Patients did not all record N and V
every day for the following reasons: too unwell (febrile, severe
mucositis etc), forgot, lost interest. Eight patients (38%) had no
vomiting at all during this study. Incidence of vomiting of any
grade peaked on day 5 (36% patients). Nausea of any grade was up
to 71% on days 3 and 4. Nausea persisted in 	50% of reporting
patients on day 12, and in 4 patients (all receiving melphalan) on
day 25. Prior chemotherapy-induced emesis was a signiﬁcant pre-
dictor of at least one vomiting episode (P  .01). Other factors
were not signiﬁcant. Conclusions: Nausea and vomiting are un-
resolved toxicities in BMT. Methodology for collecting N and V
information will be modiﬁed for an on-going study.
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RABBIT ANTI-THYMOCYTE GLOBULIN (RATG;THYMOGLOBULIN)
PHARMACOKINETICS IN PEDIATRIC PATIENTS RECEIVING A HEMATO-
POIETIC STEM CELL TRANSPLANT (HSCT)
Hale, G.A., Call, S.K., Handgretinger, R., Horwitz, E., Kasow, K.,
Barﬁeld, R., Yusuf, U., Woodard, P., Leung, W., Rodman, J. St. Jude
Children’s Research Hospital, Memphis, TN.
Objective: The pharmacokinetics of active and total rATG were
determined in children with hematologic malignancies receiving a
HSCT. Methods: Pediatric patients (n  5) undergoing HSCT
with a matched unrelated donor (MUD), non-T cell depleted
graft received 1 mg/kg rATG on day 4, then 3 mg/kg on days
3, 2, 1 (total dose 10 mg/kg). Blood samples (n  14) were
obtained from each patient at baseline, 24 hours post dose, day
0, 1, 3, 5, 7, and weeks 2, 4, 8, 12, and 24). Total rATG
by ELISA and active rATG by FACS were assayed at each time
point. Conditioning regimen consisted of fractionated TBI
(day-8 to -5) thiotepa (5 mg/kg q12h  2 doses day &minus4),
cyclophosphamide (60 mg/kg  2 days 3, 2) with cyclospor-
ine beginning day 2. Results: Intersubject variability was
substantial with a 4-fold range for total and active rATG on day
0. Total rATG was measurable in all patients through week 4
and in 4 of 5 patients at 8 weeks. Mean day 0 total rATG was 47
mcg/ml (CV 49%; range 22.6-80.7) and on day 28 was 15.5
mcg/ml (CV 41%; range 5.1-20.6). Active rATG was measur-
able in all patients through week 2, 4 of 5 patients at week 4, and
was undetectable (0.2 mcg/ml) in all patients at 8 weeks. Mean
day 0 active rATG was 2.1 mcg/ml (CV 49%, range 0.95-3.74)
and on day 28 was 0.51 mcg/ml (CV 102%; range 0.2-1.28).
Median percent active rATG after dose 1 was 14% and progres-
sively decreased during rATG administration to 4-5% on day 0
and remained similar through week 2. Median half-life for total
rATG is 15 days but could not be reliably estimated for active
rATG. All patients engrafted by day 23 (ANC 	 500), en-
grafted platelets by day 49 (20 K). There were no episodes
of grade 3-4 GVHD, 1 patient developed grade 2 GVHD, and
no grade 3 or 4 adverse rATG related events or serious infec-
tions. Conclusions: When compared to previously published
adult data (Waller et al; Biol Blood Marrow Transplant 9:460,
2003), pediatric patients have substantially lower total and active
rATG despite receiving higher doses. Differences in patient
population, dose, schedule, and sampling make comparisons
with prior studies difﬁcult. However, these initial data in chil-
dren suggest signiﬁcant differences in rATG pharmacokinetics
from adult transplant patients that preclude extrapolation of
pediatric dose regimens from adult studies.
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